Johannes Kepler University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Linz Austria (1966)

Organization Overview

First Clinical Trial
2004
NCT01560117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AKh Allgemeines Krankenhaus der Stadt Linz GmbH | AKh Linz | AKH Linz | General Hospital Linz | General Hospital Linz, Ludwig Boltzmann Gesellschaft | Johannes-Kepler-University, Department of Neurosurgery | Johannes Kepler University, Linz, Austria | Johannes Kepler University of Linz | Kepler Universitätsklinikum Gmbh | Kepler University | Kepler University Hospital | Kepler University Hospital, Department of Cardiology | Kepler University Hospital -Dpt. of Anesthesiology & Intensive Care Medicine | Kepler University Hospital Linz, Clinic for Anesthesiology and intensive care medicine | Landesnervenklinik Wagner-Jauregg | Linz General Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Iron-Deficiency (Phase 4)

Breast Neoplasms (Phase 2)

Cardiac Output, Low (Phase 2)

Cardiotoxicity (Phase 2)

Diabetes Mellitus (Phase 4)

Glioblastoma (Phase 2)

Heart Failure (Phase 3)

Hemorrhage (Phase 4)

Hyperglycemia (Phase 4)

Hyperlactatemia (Phase 4)

Infarction (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Myocardial Infarction (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 19